Shanghai Haoyuan Chemexpress Co., Ltd.

What Shanghai Haoyuan Chemexpress Co., Ltd. does

Shanghai Haoyuan Chemexpress Co., Ltd. (ChemExpress) is a Shanghai-based, publicly listed (Shanghai Stock Exchange STAR Market, 688131.SH) integrated CRO and CDMO founded in 2006 that provides contract research and contract development and manufacturing services for small molecules, biologics, and emerging modalities including antibody-drug conjugates (ADCs), peptide drug conjugates (PDCs), radionuclide drug conjugates (RDCs), peptides, and oligonucleotides. The company serves pharmaceutical and biotechnology customers globally from 10+ R&D centers and CDMO sites across China (Shanghai, Ma'anshan, Chongqing), with a US Business Center in Monmouth Junction, New Jersey supporting North American client engagement.

ChemExpress's core technical platform is organized around three service pillars. Small molecule services span drug discovery, process development, drug substance manufacturing, drug product manufacturing, regulatory CMC support, and analytical development. Bioconjugate services span ADC payload-linker development (150+ payloads, 500+ linker variants, 2,000+ synthesis records), ADC conjugation (cysteine, lysine, N-glycan, enzyme-based), ADC drug substance and formulation development, ADC manufacturing (1,500 kg/year DS, 5 million bottles/year DP, 5 OEB-5 HPAPI lines, OEL 10 ng/m³), plus emerging RDC and PDC offerings. Biologics and TIDES services span antibody discovery, antibody process development, cGMP manufacturing (~2,900L working volume, 120,000L annual design capacity), peptide manufacturing, and oligonucleotide manufacturing. Underpinning these services are enabling technology platforms including High-Throughput Experimentation (2,000+ parallel reactions per month, 90%+ scale-up consistency), Flow Chemistry, Biocatalysis (800+ enzyme library), Preparative Chromatography, Solid State Chemistry, Photochemistry, Spray Dried Dispersion, and Hot Melt Extrusion.

The company operates a fee-for-service and full-time-equivalent (FTE) professional services model across CRO and CDMO engagements, with pricing custom-quoted per project scope. Customer segments are primarily pharmaceutical and biotechnology companies requiring integrated development and manufacturing support from discovery through commercialization, including 13,000+ global partners, with named relationships spanning RemeGen (RC48 developer), Mabwell Bioscience, Insilico Medicine, and "multiple global pharmaceutical companies." The company participates in over 95% of overseas ADC/XDC transactions involving 22 Chinese developers (totaling $28 billion across 27 deals), positions its work through industry conferences (CPHI, World ADC, CDMO Live), and has demonstrated regulatory credibility via 16 FDA DMF filings, one FDA inspection passed with zero Form 483 observations, EU QP GMP audit compliance, and EcoVadis Silver Medal 2025 recognition.

Name

Shanghai Haoyuan Chemexpress Co., Ltd.

Legal name

Shanghai Haoyuan Chemexpress Co., Ltd.

Website

https://chemexpress.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Shanghai Haoyuan Chemexpress Co., Ltd. (ChemExpress) is a publicly listed Shanghai-based integrated CRO and CDMO providing contract research, development, and manufacturing services for small molecules, biologics, ADCs, peptides, and oligonucleotides to global pharmaceutical and biotechnology companies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Contract research services
• Contract manufacturing services
• Antibody drug conjugates
• API manufacturing services
• Pharmaceutical development services

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. CRO Services: Contract research services including synthetic chemistry, medicinal chemistry, process development, analytical development, and regulatory CMC support. Provided through FTE (Full-Time Equivalent) and FFS (Fee for Service) models.
2. CDMO Manufacturing: Contract manufacturing services for APIs, intermediates, drug substances, and drug products from pilot scale through commercial scale. Includes GMP manufacturing capabilities.
3. ADC/XDC Services: Integrated antibody-drug conjugate development and manufacturing services covering payload-linker synthesis, conjugation, drug substance and drug product manufacturing, and regulatory support.
4. Peptide & Oligonucleotide Manufacturing: TIDES services for peptide process development and manufacturing, and oligonucleotide process development and manufacturing.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Shanghai Haoyuan Chemexpress Co., Ltd. (ChemExpress) is a global pharmaceutical CRO and CDMO providing end-to-end drug development and manufacturing services across small molecules, biologics, and novel modalities including antibody-drug conjugates (ADCs), peptide drug conjugates (PDCs), radionuclide drug conjugates (RDCs), peptides, and oligonucleotides. Services span small molecule drug discovery, process development, cGMP drug substance and drug product manufacturing, regulatory CMC support, and analytical development, supported by proprietary enabling technology platforms such as high-throughput experimentation, flow chemistry, and biocatalysis.

Product overview

ChemExpress operates as an integrated CRO & CDMO platform offering end-to-end pharmaceutical development and manufacturing services across small molecules, biologics, and novel drug conjugates. The portfolio comprises three core service pillars: Small Molecule services (Drug Discovery, Process Development, Drug Substance Manufacturing, Drug Product Manufacturing, Regulatory CMC Support, and Analytical Development); Bioconjugates services spanning ADC Payload-Linker development (80+ payloads, 400+ linkers), ADC Conjugation, ADC Drug Substance Process Development, ADC Formulation Development, ADC Manufacturing, ADC Analytical QC, and specialized RDC and PDC offerings; and Enabling Technology Platforms including High-Throughput Experimentation, Flow Chemistry, Biocatalysis, Preparative Chromatography, Solid State Chemistry Research, Photochemistry, Spray Dried Dispersion, and Hot Melt Extrusion. The company supports projects from early discovery through commercialization with over 170 ADC projects delivered, including 5 BLA projects and 1 commercial project. Founded in 2006, the company operates R&D centers in Shanghai and Ma'anshan with manufacturing in Chongqing.

Differentiator

Problem solved

Functional benefit

Products and services

• Small Molecule Drug Discovery Comprehensive small molecule drug discovery services including synthetic chemistry and medicinal chemistry for early-stage pharmaceutical R&D, provided to pharmaceutical and biotech companies.
• Process Development API and intermediates process development as well as formulation development services bridging discovery and commercial manufacturing, for pharmaceutical clients.
• Drug Substance Manufacturing cGMP-compliant manufacturing of APIs and intermediates for clinical and commercial supply, including HPAPI manufacturing with 5 OEB-5 lines and OEL down to 10ng/m³.
• Drug Product Manufacturing Finished dosage form manufacturing including oral solids (tablets, capsules, granules, powders) and semi-solids (creams, ointments, gels).
• Regulatory CMC Support Regulatory CMC documentation preparation, US-China dual IND filing support, and communication with regulatory authorities for pharmaceutical companies.
• Analytical Development & Quality Control Method development, validation, stability studies, and ICH-compliant testing for small molecule pharmaceuticals.
• ADC Payload Linker Development and Manufacturing ADC payload and linker development covering over 150 GMP-certified cytotoxic payloads (MMAE, MMAF, exatecan mesylate, eribulin mesylate, Duocarmycin, PBD dimers) and 500+ linker variants with 2,000+ synthesis records, including 16 FDA DMF filings.
• ADC Conjugation Site-specific and non-site-specific bioconjugation technologies including cysteine-based, lysine-based, N-glycan conjugation, and enzyme conjugations for ADC development, with 170+ ADC projects delivered.
• ADC Drug Substance Process Development ADC drug substance process development from Payload-Linker synthesis through conjugation, with IND-stage turnaround achievable in 3-4 months.
• ADC Formulation Development ADC formulation development services including aqueous injections and lyophilized formulations aligned with target product profiles.
• ADC Manufacturing cGMP-compliant ADC bioconjugate manufacturing for R&D, clinical, and commercial stages with 5 OEB-5 compliant high-potency lines, 1,500 kg/year drug substance capacity, and 5 million bottles/year fill-finish capacity.
• ADC Analytical Development & Quality Control Complete analytical services for ADC drug development including structural characterization, impurity analysis, microbial safety control, and stability studies.
• Radionuclide Drug Conjugates (RDC) Co-development of RDC substance processes from targeted ligands, linkers, and chelators to cold-label compound synthesis.
• Peptide Drug Conjugates (PDC) End-to-end PDC drug development leveraging extensive peptide services and Payload-Linker technology platform.
• Antibody Drug Discovery Monoclonal, bispecific, and multispecific antibody discovery services for biotech and pharmaceutical clients.
• Antibody Process Development Cell culture and purification process development for antibody manufacturing.
• Biologics Antibody Manufacturing Full lifecycle antibody solutions including GMP manufacturing with ~2,900L capacity, producing in 200L, 500L, 2,000L scales with 120,000L annual design capacity.
• Peptide Process Development & Manufacturing Peptide process development and manufacturing services under cGMP conditions for pharmaceutical and biotech clients.
• Oligonucleotide Process Development & Manufacturing Oligonucleotide process development and manufacturing services for TIDES modality.
• High-Throughput Experimentation (HTE) Platform Parallel execution platform enabling 2,000+ reactions per month with reduced material consumption and 3-5x faster R&D iteration for reaction optimization and catalyst screening, with 90%+ scale-up consistency.
• Flow Chemistry Platform Continuous manufacturing platform for process development and manufacturing from pre-clinical to commercialization, supporting high-temperature, high-pressure, and hazardous reactions.
• Biocatalysis Platform One-stop biocatalysis solution with 800+ enzyme library for screening, fermentation, process development, and cGMP production at scale from hundreds of grams to hundreds of kilograms.
• Preparative Chromatography Service GMP preparative chromatographic services for separation, purification, and production of APIs and advanced intermediates from milligram to kilogram scale using prep-HPLC and prep-SFC systems.
• Solid State Chemistry Research Polymorph screening and scale-up from free form through commercial ton-scale production, including formulation R&D services.

Quantifiable outcome

• 2,000+ parallel reactions per month capacity with HTE platform
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature8 records

Partnerships

Four partnerships are on record, tiered core.

• Mabwell Bioscience (688062.SH)coreStrategic or Co-development Partner · 17 September 2025Strategic cooperation agreement announced September 17, 2025 between ChemExpress, Mabwell Bioscience, and Insilico Medicine. Partnership establishes novel ABC (AI+BioTech/BioPharma+CRO/CDMO) model for ADC drug development, creating an ADC compound library covering hundreds of targets and screening next-generation ADC candidates.
• Insilico MedicinecoreStrategic or Co-development Partner · 17 September 2025Three-way strategic cooperation with ChemExpress and Mabwell Bioscience to integrate AI power, biotech drive, and CRO/CDMO implementation for ADC drug development. Joint establishment of novel ADC compound library and screening of next-generation candidates.
• AbTis Co., Ltd.coreStrategic or Co-development Partner · 12 May 2025Strategic cooperation agreement signed on May 12, 2025 between Shanghai Haoyuan Chemexpress and AbTis, a South Korean ADC biotechnology company. The partnership aims to accelerate the development of new generation ADC drugs through combined expertise in ADC technology platforms.
• Chinese ADC/XDC DeveloperscoreGTM or Marketing PartnerChemExpress has participated in over 95% of overseas ADC/XDC transactions involving the 22 Chinese companies with such deals, providing technical services and supply of intermediates. Total overseas XDC transactions reached $28 billion across 27 deals.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• WuXi XDC (Cayman) Inc. Hong Kong-listed bioconjugate/ADC-focused CDMO spun out of WuXi Biologics; offers payload-linker, conjugation, and ADC drug substance/product manufacturing. The closest direct competitor to ChemExpress in ADC CDMO, with overlapping Chinese biotech customers and comparable technology platforms.
• WuXi Biologics: Hong Kong-listed global biologics CDMO with leading antibody and bioconjugate manufacturing capacity. Comparable to ChemExpress on biologics antibody services and adjacent on ADC drug substance manufacturing via WuXi XDC.
• Pharmaron: China-based integrated CRO/CDMO offering small-molecule, biologics, and CMC services from discovery through manufacturing. Comparable end-to-end platform positioning, with stronger UK/US footprint and broader small-molecule emphasis.
• Asymchem Laboratories: China-based listed CDMO with strong small-molecule API and peptide CDMO capabilities and growing bioconjugate exposure. Comparable to ChemExpress on small-molecule drug substance, process development, and emerging peptide/oligonucleotide services.
• Hangzhou DAC Biotech: China-based ADC-focused CDMO specializing in payload-linker synthesis, bioconjugation, and ADC manufacturing. Directly comparable to ChemExpress' bioconjugate offering and competes for many of the same Chinese ADC developers.

Broad incumbents

• Lonza Group: Swiss global CDMO leader with leading positions in biologics, cell and gene therapy, and small molecules. Overlaps with ChemExpress on small-molecule API manufacturing, HPAPI, and bioconjugate services, but operates at vastly greater scale and global reach.
• WuXi AppTec: China-headquartered global CRO/CDMO with the broadest service portfolio in the industry spanning discovery, preclinical, and commercial manufacturing. Overlaps with ChemExpress across most service lines but as a much larger, more diversified incumbent.
• Catalent (Thermo Fisher Scientific): Global CDMO now part of Thermo Fisher with leading biologics, oral solid, and bioconjugate capabilities. Comparable to ChemExpress on drug product manufacturing, ADC fill-finish, and integrated development services as part of a broader portfolio.

Emerging players

• AbTis Co., Ltd. South Korean ADC biotech developing site-specific conjugation technology; signed a May 2025 strategic cooperation agreement with ChemExpress. Comparable ADC technology peer and strategic partner, though smaller and earlier-stage than ChemExpress.
• Bachem: Swiss-listed peptide and oligonucleotide CDMO leader expanding into bioconjugates. Comparable to ChemExpress' TIDES peptide/oligonucleotide services and PDC offering, though Bachem is the established global incumbent in TIDES CDMO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/haoyuan-chemexpress-co-ltd

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shanghai Haoyuan Chemexpress Co., Ltd.